Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240020/S001

TOUCH CMC 1 Prosthesis

Keri Medical SA · Decision date Sep 5, 2025

FDA DECISIONP240020/S001

What did the FDA approve?

FDA records P240020/S001 as a supplement to PMA P240020, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Sep 5, 2025.

FDA approval order statement

Approval of the protocol for the post-approval study (PAS), Continued Long-Term Follow-up Study. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240020.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Orthopedic
Decision date
Sep 5, 2025
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P240020/S001
Regulatory pathway
PMA supplement
Product code
SFA
Decision code
APPR
Decision date
Sep 5, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, finger, semi-constrained, metal/polymer.

Product code
SFA
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P240020/S001 received

    Application receipt date recorded by FDA.

  2. P240020/S001 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P240020. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240020

Product / regulatory recordCompanyPathwayDecision dateSource
Keri Medical SAPMA supplementSep 5, 2025FDA
Keri Medical SAPMA supplementDec 17, 2025FDA
Keri Medical SAPMA supplementApr 13, 2026FDA
Keri Medical SAPMA supplementMay 12, 2026FDA
Keri Medical SAPMA supplementJun 24, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Keri Medical SA

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Chemin Du Pre-Fleuri 5, 1228 Plan-Les-Ouates

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records